Ixiaro (IC51) / Valneva - LARVOL DELTA

Safety profile of Japanese encephalitis vaccines: a comprehensive analysis of vaccine adverse event reports from 1993 to 2025. (PubMed, Front Public Health) - "IXIARO accounted for 3,452 pairs, JE-VAX 1368, J-VAX 698, and "unspecific Brand" 1,078...The observed overlap between spontaneous reporting and online search trends suggests public awareness and information dissemination influence reporting patterns. These findings underscore the need for continued JEV safety surveillance and further investigation."

Adverse events • Journal • Allergy • CNS Disorders • Dermatology • Epilepsy • Immunology • Pruritus • Urticaria

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (clinicaltrials.gov) - P1/2 | N=402 | Recruiting | Sponsor: SK Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease

Bioinformatics Analysis of Antibody Repertoire in Flavivirus-Naïve and Experienced Individuals Following Zika Vaccination (ASTMH 2024) - "Blood samples from 47 donors across four cohorts, characterized by flavivirus exposure history (naïve or with prior immunizations against YFV (YF-VAX ® ) or JEV (IXIARO ® )), were collected at key time points before and after ZPIV vaccination...Our data suggest that past flavivirus immunization shapes the immune landscape, promoting cross-reactive antibodies following Zika vaccination. These results underscore the importance of considering individual vaccination and flavivirus exposure histories in ZIKV vaccine strategies."

Clinical • Late-breaking abstract • CNS Disorders • Dengue Fever • Immunology • Infectious Disease

B cell responses to a Zika purified inactivated vaccine are shaped by previous immunization with Japanese encephalitis and Yellow fever vaccines (ASTMH 2024) - "We evaluated antibody responses in a phase I clinical study representing 3 groups: (group a) flavivirus-naïve individuals vaccinated with a Z ika p urified i nactivated whole v irus vaccine (ZPIV), (group b) JEV (IXIARO ® ) followed by ZPIV, and (group c) YFV (YF-VAX ® ) followed by ZPIV...These studies demonstrate the elicitation of cross-reactive B cells following flavivirus vaccination, and provide insights into the memory recall B cell response upon subsequent flavivirus exposure. Characterizing these cross-reactive B cell populations and specificities is a critical step towards eliciting cross-protective responses following flavivirus vaccination."

CNS Disorders • Dengue Fever • Infectious Disease

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (clinicaltrials.gov) - P1/2 | N=402 | Not yet recruiting | Sponsor: SK Bioscience Co., Ltd.

New P1/2 trial • CNS Disorders • Infectious Disease

Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact. (PubMed, Viruses) - "Fortunately, unlike the other virus invaders mentioned above, an inactivated whole virus JE vaccine (IXIARO) has been approved by the US Food and Drug Administration for human use in advance of a public health emergency, but there is no veterinary vaccine. This paper describes the risks and potential consequences of the introduction of JEV into the US, the need to integrate planning for such an event in public health policy, and the requirement for additional countermeasures, including antiviral drugs and an improved single dose vaccine that elicits durable immunity in both humans and livestock."

Journal • Chikungunya • CNS Disorders • Infectious Disease

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial. (PubMed, Lancet Infect Dis) - P1 | "We found ZPIV to be well tolerated in flavivirus naive and primed adults but that immunogenicity varied significantly according to antecedent flavivirus vaccination status. Immune bias towards the flavivirus antigen of initial exposure and the timing of vaccination may have impacted responses. A third ZPIV dose overcame much, but not all, of the discrepancy in immunogenicity. The results of this phase 1 clinical trial have implications for further evaluation of ZPIV's immunisation schedule and use of concomitant vaccinations."

Clinical • Journal • P1 data • Allergy • CNS Disorders • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Pain

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Singapore General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease

Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019. (PubMed, Vaccine) - "Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC; Ixiaro) was approved in the United States in 2009...Only delayed hypersensitivity reactions occurred more frequently following JE-VC (rate ratio: 4.2, 95 % CI 1.2-15.3; p = 0.03), but rates were low for both vaccines. These results support JE-VC's safety."

Adverse events • Journal • Preclinical • CNS Disorders • Epilepsy • Immunology • Infectious Disease

A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine. (PubMed, J Travel Med) - "The rapid development and production of a ZIKV vaccine candidate building on a commercial Vero-cell manufacturing platform resulted in a safe and immunogenic vaccine suitable for further clinical development. To optimize antibody persistence, higher doses and a booster administration might be considered."

Journal • P1 data • Preclinical • CNS Disorders • Infectious Disease

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (clinicaltrials.gov) - P2 | N=70 | Not yet recruiting | Sponsor: Singapore General Hospital

New P2 trial • CNS Disorders • Infectious Disease

Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia. (PubMed, Hum Vaccin Immunother) - "Using data from SmartVax, an active surveillance system for monitoring vaccine safety, adverse events following immunizations (AEFIs) were compared between the two JE vaccines available in Australia (a chimeric live attenuated vaccine [Imojev] and a Vero cell-derived inactivated vaccine [JEspect])...Both JE vaccines available in Australia are safe and well tolerated. Odds of AEFIs were age-dependent, young children should be carefully observed for AEFIs after vaccination."

Journal • CNS Disorders

"$VALN Valneva: U.S. DoD Exercises First Year Option on IXIARO® Supply Contract https://t.co/FtEofXDuqB" (@otcdynamics)

"Što se tiče cjepiva Hrvatska je poduzela sve što je potrebno kako bismo ih čim prije dobili, nakon što budu potvrđena od strane @EMA_News, te ćemo osigurati da distribucija bude pravovremena i pravična." (@VladaRH)

"4 500 000 doza cjepiva, za koga ste to kupili i za koje novce?" (@listovaca)

"U dogovoru s @EU_Commission zaključili smo sporazume o kupnji cjepiva unaprijed. Od @AstraZeneca smo naručili više od 2 milijuna doza, s @JNJNews smo dogovorili 900 tisuća doza cjepiva, a od @Pfizer smo naručili i rezervirali milijun doza cjepiva. (1/2)" (@VladaRH)

"(2/2) Većina tih farmaceutskih divova očekuje da će se cjepiva odobriti do siječnja ili veljače, mi smo osigurali potreban broj doza i već ćemo tada moći na drugi način gledati na epidemiju." (@VladaRH)

Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study. (PubMed, Vaccine) - P3 | "These data indicate that vaccination with IXIARO® is able to induce protective titers that persist up to 60 months after the primary immunization. Clinical trial registry number NCT00596102."

Clinical • Journal • CNS Disorders

Description of 47 new species of the New Caledonian endemic caddisfly genus Agmina Ward & Schefter (Trichoptera, Ecnomidae). (PubMed, Zookeys) - "Additionally, new records are provide for the species A. acula Ward, 2003, A. artarima Ward & Schefter, 2000, A. berada Ward & Schefter, 2000, A. bimaculata Ward & Schefter, 2000, A. cheirella Ward, 2003, A. comata Ward, 2003, A. diriwi Ward & Schefter, 2000, A. hamata Ward & Schefter, 2000, A. hastata Ward & Schefter, 2000, A. hirta Ward & Schefter, 2000, A. jepiva Ward & Schefter, 2000, A. joycei Ward & Schefter, 2000, A. kapiwa Ward & Schefter, 2000, A. kara Ward & Schefter, 2000, A. mariae Ward & Schefter, 2000, A. nodosa Ward, 2003, A. panda Ward & Schefter, 2000, A. padi Ward & Schefter, 2000, A. parie Ward & Schefter, 2000, A. rhara Ward & Schefter, 2000, A. urugi Ward & Schefter, 2000, and A. vuegi Ward & Schefter, 2000. With a total of 75 described species Agmina is one of the largest animal radiations in New Caledonia. Nothing is known about the early stages of any of the species in this..."

Journal

"Osiguarti treba samo jedno PRAVO IZBORA! To znači ponuda više mogućnosti! Cjepivo, bolovanje kao svako drugo bez izolacije uz PRAVILNU terapiju (ona postoji)! HITNA PZZ COVID-19., putovanja kao do sada uz zaštitu da se uopće ne oboli, dolazak na posao uz zaštitu da se ne oboli..." (@nadaly_Nada)

Infectious Disease • Novel Coronavirus Disease

Japanese Encephalitis Vaccine. (PubMed, R I Med J (2013)) - "The ACIP has recently expanded guidelines on the use of Ixiaro, the inactivated Japanese encephalitis vaccine. This article reviews the disease burden of Japanese encephalitis and the role of a travel clinic in guiding travelers to Asia regarding decision-making about the use of this highly protective vaccine."

Journal • CNS Disorders

"#Koronavirus | @EU_Commission zaključila je preliminarne razgovore o nabavi potencijalnog cjepiva protiv bolesti COVID-19. Predviđeni ugovor s poduzećem @sanofi omogućio bi kupnju cjepiva svim državama članicama. @koronavirus_hr @VladaRH @EP_Zagreb @RavnateljstvoCZ @ViliBeros" (@EK_Hrvatska)

Infectious Disease • Novel Coronavirus Disease

Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Humans is Diminished by Priming with a Yellow Fever or Japanese Encephalitis Virus Vaccine: Elucidating Immunologic Interference between Flavivirus Vaccines (IMMUNOLOGY 2020) - "Group 1 only received ZPIV, while Groups 2 and 3 first received either licensed Japanese encephalitis (IXIARO) or yellow fever (YF-VAX) vaccine two-months prior to receiving ZPIV...These results indicate the interplay of flavivirus immunity is contextual and likely specific to the mode and timing of antigen presentation. More studies are needed to investigate these factors, so as to optimize the rational use of vaccines against co-endemic flaviviruses."

"Ovaj tjedan u tijeku je Europski tjedan imunizacije #EIW. 🇪🇺💉 Goruće pitanje današnjice razvoj je sigurnog i učinkovitog cjepiva za #koronavirus. @koronavirus_hr @WHO_Europe @ECDC_EU @EMA_News #VaccinesWork #protectedtogether @ViliBeros @EP_Zagreb" (@EK_Hrvatska)

Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study. (PubMed, Travel Med Infect Dis) - P3; "The substantial decline in GMT observed in this study, together with previously published data on children vaccinated with IXIARO® support the recommendation for a booster dose in children who remain at risk of JE from 1 year after the primary series of IXIARO®, consistent with the recommendation for adults."

Clinical • Journal • P3 data